The following table summarizes the components of stock-based compensation expense recognized in the Company’s condensed statements of operations and comprehensive loss during the three and six months ended June 30, 2026 and 2025 (in thousands):


	Three Months Ended June 30,					Six Months Ended June 30,
	2026		2025			2026		2025
Research and development	$	235	$	(424	)	$	389	$	(298	)
General and administrative		636		347			1,171		765
Total stock-based compensation expense	$	871	$	(77	)	$	1,560	$	467

During the six months ended June 30, 2026, the Company granted 83,050 RSUs with a weighted-average grant date fair value of $73.06 per unit, of which 36,900 RSUs are subject to performance-based vesting conditions related to the satisfaction of a regulatory milestone. As of June 30, 2026, the Company had 38,920 RSUs outstanding subject to performance-based vesting conditions, of which none are considered probable of achievement.